Search

Mersalyl

Mersalyl is the sodium salt form of mersalyl acid, a mercurial diuretic. It is an outdated drug, and its approval has been discontinued by the FDA. … The sodium salt of a mercury-containing derivative of salicylamide, was formerly used (often in combination with theophylline) to treat edema, due to its powerful diuretic properties [L1577].

Corticorelin

Corticotropin-releasing factor is studied in the treatment of brain cancer. It is made naturally by the hypothalamus (a part of the brain) and can also be made in the laboratory. … Human corticotropin-releasing factor may help reduce symptoms caused by edema (swelling) of the brain. It is a type of neurohormone, also called hCRF.

Cyanocobalamin Co-60

Cyanocobalamin Co-60 was used for the diagnosis of pernicious anemia, but now it is withdrawn from the market in the US for unknown reasons. … Cyanocobalamin Co-60 is an analog of Vitamin B12 labeled with Co60.

Albinterferon Alfa-2B

The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C. … Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B, and a broad range of cancers.

Estramustine phosphate

A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.

Vapreotide

Vapreotide is a synthetic octapeptide somatostatin analog. It was being studied for the treatment of cancer.

Fasedienol

PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). … It is a member of a new family of pharmaceutical compounds called vomeropherins.

XL019

XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. An IND for XL019 was filed by Exelixis in May 2007.

Ulotaront

Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5 … SEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia.

Promegestone